SYnAbs S.A. of Gosselies at MEDICA 2021 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

SYnAbs S.A.

48, rue Auguste Piccard, 6041 Gosselies
Belgium
Telephone +32 71 374880, +32 48 3743904
isoardj@synabs.be

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

This company is co-exhibitor of
Wallonia Export & Investment (AWEX)

Hall map

MEDICA 2021 hall map (Hall 1): stand E53

Fairground map

MEDICA 2021 fairground map: Hall 1

Contact

Julien Isoard

Phone
+32 483 743 904

Email
isoardj@synabs.be

Please log in

You must be logged in to use matchmaking

Please log in for matchmaking

Registration is required to use the networking service and a separate registration for matchmaking. Please register for Matchmaking first.

Let's get started!

Welcome to Matchmaking. Would you like to get in touch with ?

Our products

Product category: Immuno assay testing

Anti-hemoglobin rat and mouse monoclonal antibodies

  • IgG1 kappa rat anti-hemoglobin A (HbA)
  • IgG1 kappa mouse anti-hemoglobin C (HbC)
  • IgG1 kappa rat anti-hemoglobin E (HbE)
  • IgG1 kappa rat anti-hemoglobin E (HbS)
  • IgG1 mouse anti-total hemoglobin

More Less

Product category: Immuno assay testing

Irrelevant isotype control IgGs: anti-DNP monoclonal antibodies (rat and mouse mAbs)

  • IgG1 kappa rat anti-dinitrophenyl hapten
  • IgG2a kappa rat anti-dinitrophenyl hapten
  • IgA kappa rat anti-dinitrophenyl hapten
  • IgE kappa rat anti-dinitrophenyl hapten
  • IgM kappa rat anti-dinitrophenyl hapten
  • IgG2a kappa mouse anti-dinitrophenyl hapten
  • IgG2b kappa mouse anti-dinitrophenyl hapten
  • IgG3 kappa mouse anti-dinitrophenyl hapten
  • IgM mouse anti-dinitrophenyl hapten

More Less

Product category: Immuno assay testing

Anti-Androstenedione Rat and Mouse monoclonal antibodies

  • Mouse anti-androstenedione monoclonal antibody
  • Rat anti-androstenedione monoclonal antibody

More Less

Product category: Immuno assay testing

Anti-DiHydroTestosterone Guinea Pig monoclonal antibodies

  • Anti-DiHydroTestosterone Guinea Pig monoclonal antibodies

More Less

Product category: Immuno assay testing

Anti-His tag rat monoclonal antibodies (mAbs)

  • IgG2b kappa rat anti-His tag (C-ter & N-ter)
Reference validated on 17 different recombinant proteins
Detect both N-terminal & C-terminal sequences
Description: IgG2b kappa rat anti-His Tag
Class: monoclonal
Type: primary 
Host/Isotype : rat

More Less

Product category: Immuno assay testing

Secondary Monoclonal Antibodies

  • Anti-mouse rat monoclonal antibodies
  • Anti-rat mouse monoclonal antibodies
  • Anti-human rat and mouse monoclonal antibodies
  • Anti-rabbit monoclonal antibodies

More Less

Product category: Immuno assay testing

Custom antibody development against haptens and membrane receptors

Thanks to smart antigen design strategies, SYnabs direct the immune response towards the most appropriate epitope. As a complete service, SYnAbs is able to design, synthesize, and conjugate antigens for use as immunogens for monoclonal antibody development programs to target:
  • chemical drug (valproic acid,...) 
  • steroids (androstenedione, DHT...)
  • peptides
  • toxins (aflatoxin, ricin, anthrax...)
  • epigenetic modifications (Me, Ac,...on histones)
  • polysaccharides (galactomannan, N-glycan, O-glycan...)
  • complex transmembrane proteins (GPCR, ion channel, tyrosine kinase receptor, proteins from the viral envelope...)

More Less

Company news

Date

Topic

18 Oct 2021

SYnAbs ink strategic agreement on epigenetics

SYnabs and Belgian Volition SRL are proud to announce the signature of a strategic collaborative agreement. As part of this ambitious 28-months project supported with funding from the Walloon Region, the two Walloon companies have planned the generation of innovative Nu.Q® immunoassays, targeting 16 new epigenetic biomarkers.

Within this consortium, Volition will identify the biomarkers of interest - epigenetic modifications of histones and DNA, histone variants or proteins associated with nucleosomes - and combine them to increase the sensitivity and clinical specificity of its non-invasive Nu.Q® assays.

SYnAbs' proprietary DNA immunization and rat immune tolerance disruption technologies will allow the generation of highly specific monoclonal antibodies against epigenetic modifications on circulating nucleosomes.

The combined expertise of the two companies will result in the precise quantification of these biomarkers to ensure the early diagnosis and monitoring of the efficacy of oncology treatments, in both humans and animals.

More Less

18 Oct 2021

SYnabs therapeutic and R&D tools targeting human CD

CD (cluster of differentiation) molecules are membrane receptors important for immune cell function. They are found on the cell surface and can be entirely extracellular or transmembrane.

While it may seem easy to recognize an extracellular loop by injecting the dedicated peptide epitope, acting on a cell membrane glycoprotein is another matter.

The production of a functional antibody against a transmembrane receptor can be achieved by the unique combination of presenting the native conformation of the antigen to the immune system, excluding irrelevant plasma cell populations and isolating rare clones secreting the antibody of interest.

This was achieved by SYnabs by performing DNA immunization followed by syngeneic whole-cell immunization in proprietary LOU rat species.

We generated LO-CD2a (BTI-322), a functional rat human anti-CD2, which has been shown to have potential use as a T-cell depleting agent (3). Under license from Medimmune, the human version of LO-CD2a was named MEDI-507 and is now known as Siplizumab. Afterward, AstraZeneca subsequently licensed the product to ITBMed Biopharmaceuticals for further organ transplantation testing. Since the beginning of the study, AstraZeneca has been able to generate safety data on more than 400 patients.

In parallel, SYnAbs has generated LO-CD2b and LO-TACT, a therapeutic rat anti-human CD25 (IL2Ra) depleting antibody, already chimerized and tested in clinical trials.

More Less

18 Oct 2021

SYnAbs therapeutic anti-chemokine receptors monoclonal antibodies

Exclusive to vertebrates, chemokines (also called intercrines, or chemotactic cytokines) are a family of highly conserved secreted proteins of 8-15 kDa size, whose main role is to control immune cell trafficking, mainly leucocytes. An important attribute of chemokines is that they can be produced by the very cells they attract to inflammatory sites.

Chemokine ligands interact with 7-transmembrane-spanning family of 19 canonical specific receptors (cCKRs) and 4 atypical chemokine receptors (ACKRs). Together, these 23 chemokines receptors form the class A G-protein-coupled receptors (GPCRs) family. The atypical receptors, expressed by non-leukocyte cell types, have the particularity of being able to trigger signals through non-G protein-coupled mechanisms.

The 46 human chemokines have been classified into four classes depending on the number and positioning of four conserved cysteine residues (Oppenheim et al., 1991; Schall, 1991), giving birth to C, CC, CXC, and CX3C families.

More Less

18 Oct 2021

SYnAbs Functional B-cell depleting monoclonal antibodies (mouse & rat)

To address all B cell depletion needs, SYnAbs has developed monoclonal antibody references, which exhibit the ability to deplete murine or rat B cells in vivo, providing a valuable research tool for its biotech and pharma partners.

In fact, Chentoufi et al demonstrated that in adult mice sequential treatment with SYnAbs LO-MD anti-δ and then SYnAbs LO-MM anti-μ induces a complete depletion of B cells and xenoreactive natural antibodies (XNA) and represents a potential approach to induce xenograft tolerance (3).

In parallel, Bazin et al showed that anti-µ suppression was demonstrated to be effective on rat IgM, IgA, and IgG classes but also on IgD and IgE classes and on the four subclasses of IgG via the injection of SYnAbs MARM anti-μ and SYnAbs MARD anti-δ antibodies (4).

Finally, Soares et al concluded that the obtained data suggested that SYnAbs MARM anti-mu administration in adult rats results in the early arrest of B cell differentiation in the bone marrow, which causes the down-regulation of IgM production. Furthermore, anti-mu mAb administration directly or indirectly activates a particular subset of mature B cells, which differentiates into IgG2c-secreting cells (5).

(3)  Chentoufi, Aziz Alami; Nizet, Yannick; Havaux, Xavier; De La Parra, Bernardo; Cormont, Françoise; Hermans, Dominique; Bazin, Hervé; Latinne, Dominique DIFFERENTIAL EFFECTS OF INJECTIONS OF ANTI-μ AND ANTI-δ MONOCLONAL ANTIBODIES ON B-CELL POPULATIONS IN ADULT MICE, Transplantation: December 15, 1999 - Volume 68 - Issue 11 - p 1728-1736

(4)  Bazin H, Platteau B, Beckers A, Pauwels R. Differential effect of neonatal injections of anti-mu or anti-delta antibodies on the synthesis of IgM, IgD, IgE, IgA, IgG1, IgG2a, IgG2b, and IgG2c immunoglobulin classes. J Immunol. 1978 Nov;121(5):2083-7. PMID: 101595.

(5)  Soares M, Havaux X, Nisol F, Bazin H, Latinne D. Modulation of rat B cell differentiation in vivo by the administration of an anti-mu monoclonal antibody. J Immunol. 1996 Jan 1;156(1):108-18. PMID: 8598450.

 

More Less

18 Oct 2021

SYnAbs Anti-CD25/IL2Ra therapeutic monoclonal antibody LO-TACT-1

After the first success in 1990, Baudreuil et al decided to launch a randomized long-term study to test the LO-TACT-1 rat-LOU monoclonal anti-interleukin 2 receptor (IL2Ra/CD25) monoclonal antibody generated by SYnAbs, in the context of acute and chronic allograft rejection, also with infectious diseases following kidney transplantation.

During ten years, LO-TACT-1 (10mgr/day iv) demonstrated fewer bacterial and viral infections, and less cases of rejection, compared to anti-thymocyte globulin (Thymoglobuline MERIEUX, 15mg/day) treatment in forty grafted patients. Long-term graft survival was the first endpoint, and the number of cases of acute cellular and chronic rejection and the frequency of infectious events were the secondary end-points.

So far, LO-TACT-1 has never been tested in oncology and could show interesting results.

  • Hiesse C, Kriaa F, Alard P, et al. Prophylactic use of the IL-2 receptor-specific monoclonal antibody LO-Tact-1 with cyclosporin A and steroids in renal transplantation. Transpl Int 1992; 5 (Suppl. 1): S444
  • Beaudreuil S et al. (2006) Long-term results (10 years) of a prospective trial comparing Lo-tact-1 monoclonal antibody and anti-thymocyte globulin induction therapy in kidney transplantation. Transpl Int 19: 814–820

More Less

About us

Company portrait

SYnAbs' mission is to generate innovative antibodies against poor immunogenic compounds (steroids, small molecules, carbohydrates, epigenetic modifications) and complex antigens (GPCR, ion channels, toxins, transporters, proteins from viral envelopes) thanks to unique technologies (DNA immunization, syngeneic cell immunization, rat-LOU species). Anti-drug antibodies, surrogates, or therapeutics mAbs one-stop-shop solution from antigen to gr manufacturing.